Article
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Lung cancer (Amsterdam, Netherlands) - 1 May 2022
Steeghs Elisabeth M P, Groen Harry J M, Schuuring Ed, Aarts Mieke J, Damhuis Ronald A M, Voorham Quirinus J M, Ligtenberg Marjolijn J L, Grünberg Katrien
Abstract excerpt
OBJECTIVES: The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-expanding and requires testing of an increasing number of predictive biomarkers. We present a comprehensive real-world evaluation of molecular testing and treatment selection in stage IV NSCLC patients in the Netherlands from 2017 to 2019. MATERIALS AND METHODS: Molecular pathology reports of NSCLC patients were collected from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
